Monte Rosa Therapeutics (GLUE) Return on Equity (2023 - 2025)
Historic Return on Equity for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to 0.08%.
- Monte Rosa Therapeutics' Return on Equity rose 6400.0% to 0.08% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.08%, marking a year-over-year increase of 6400.0%. This contributed to the annual value of 0.36% for FY2024, which is N/A changed from last year.
- According to the latest figures from Q3 2025, Monte Rosa Therapeutics' Return on Equity is 0.08%, which was up 6400.0% from 0.09% recorded in Q2 2025.
- Over the past 5 years, Monte Rosa Therapeutics' Return on Equity peaked at 0.09% during Q2 2025, and registered a low of 0.82% during Q1 2024.
- For the 3-year period, Monte Rosa Therapeutics' Return on Equity averaged around 0.37%, with its median value being 0.45% (2024).
- Per our database at Business Quant, Monte Rosa Therapeutics' Return on Equity skyrocketed by 4000bps in 2024 and then surged by 8400bps in 2025.
- Monte Rosa Therapeutics' Return on Equity (Quarter) stood at 0.74% in 2023, then skyrocketed by 54bps to 0.34% in 2024, then soared by 124bps to 0.08% in 2025.
- Its Return on Equity stands at 0.08% for Q3 2025, versus 0.09% for Q2 2025 and 0.02% for Q1 2025.